BioSpace News Archive

Increase in Incidence of Gastrointestinal Cancers to Act as Growth Levers for Endoscopy Ultrasound Market

Endoscopy ultrasound market is projected to expand substantially at a CAGR of 5.7% during the forecast period.

June 24, 2022
·
6 min read
BCG Vaccines Market: Rapid Advancements in Technology in the Field of Medical Research on Vaccines to Drive the Market

Wilmington, Delaware, United States: Currently, BCG vaccine is the only available vaccine for tuberculosis.

June 24, 2022
·
5 min read
Global Osteoporosis Therapeutics Market Stands At A Valuation Of US$ 12.7 Bn Currently, Predicted To Reach US$ 14.2 Bn By The End Of 2026.

Fact.MR – A Market Research and Competitive Intelligence Provider: Demand for osteoporosis therapeutics is anticipated to increase at a CAGR of 2.9% from 2022 to 2026, as per this new analysis by Fact.MR, a market research and competitive intelligence provider.

June 24, 2022
·
7 min read
Pain Management Therapeutics Market: Global Industry Analysis | Forecast (2021-2031)

Pain is invariably around whenever a body is suffering from diseases, which can be of multiple types including fibromyalgia, stomach ulcer, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer.

June 24, 2022
·
8 min read
Business

Availability of the Q2 2022 Memorandum for modelling purposes

Sanofi announced that its Q2 2022 Memorandum for modelling purposes is available on the “Investors” page of the company’s website:

June 24, 2022
·
4 min read
Biotech Bay

Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)

Mirum Pharmaceuticals, Inc. presented data at the International Liver Congress™ of The European Association for the Study of the Liver in London, United Kingdom.

June 24, 2022
·
10 min read
Drug Development

Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.

Green3Bio, a subsidiary of Greenfire Bio, announced a publication in the Journal of Clinical Investigation1 led by researchers at The University of Texas MD Anderson Cancer Center demonstrating that SIK2 inhibitors, including GRN-300 sensitized ovarian and triple-negative breast cancer cells and xenografts to PARP inhibitors.

June 24, 2022
·
5 min read
Genetown

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt today announces that the company plans to submit a Formal Dispute Resolution Request (FDRR) for the company’s New Drug Application (NDA) for Oleogel-S10 (Filsuvez®), for the treatment of the cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa (EB).

June 24, 2022
·
7 min read
Policy

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection

Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection.

June 24, 2022
·
45 min read
Business

Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its fourth quarter fiscal 2022 key financial results and provided an update on recent business developments and key upcoming milestones.

June 24, 2022
·
16 min read